Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis
- 30 April 2004
- Vol. 34 (5) , 890-899
- https://doi.org/10.1016/j.bone.2004.01.008
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Toxic acute tubular necrosis following treatment with zoledronate (Zometa)Kidney International, 2003
- Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeysBone, 2003
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- Intermittent versus continuous clodronate administration in postmenopausal women with low bone massBone, 2000
- Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral PropertiesJournal of Bone and Mineral Research, 1999
- Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 1997
- Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopauseOsteoporosis International, 1994
- Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaBone and Mineral, 1991
- Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosisBone and Mineral, 1991
- RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATESThe Lancet, 1983